Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis

by | May 22, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company has received Fast Track Designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS).


Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner